Glenmede Trust Co. NA Cuts Stock Position in Neogen Corporation $NEOG

Glenmede Trust Co. NA lessened its holdings in shares of Neogen Corporation (NASDAQ:NEOG) by 7.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,829,298 shares of the company’s stock after selling 144,411 shares during the quarter. Glenmede Trust Co. NA’s holdings in Neogen were worth $16,994,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in NEOG. UMB Bank n.a. grew its holdings in shares of Neogen by 238.2% in the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company’s stock valued at $45,000 after purchasing an additional 4,523 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Neogen by 816.9% during the 4th quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company’s stock worth $53,000 after buying an additional 6,764 shares in the last quarter. Cresset Asset Management LLC purchased a new position in Neogen in the 2nd quarter valued at approximately $53,000. Evergreen Capital Management LLC purchased a new position in Neogen in the 2nd quarter valued at approximately $56,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Neogen by 3,158.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company’s stock worth $58,000 after acquiring an additional 8,054 shares in the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NEOG. Weiss Ratings lowered Neogen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.67.

Neogen Trading Up 4.4%

NASDAQ:NEOG opened at $12.04 on Friday. Neogen Corporation has a 1 year low of $4.56 and a 1 year high of $12.15. The stock has a market cap of $2.62 billion, a P/E ratio of -401.33, a P/E/G ratio of 5.39 and a beta of 1.80. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.84 and a current ratio of 3.82. The stock has a 50-day simple moving average of $9.44 and a 200-day simple moving average of $9.62.

Neogen (NASDAQ:NEOG) last issued its earnings results on Thursday, July 30th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.03. The business had revenue of $225.30 million for the quarter, compared to analyst estimates of $212.35 million. Neogen had a positive return on equity of 2.78% and a negative net margin of 0.91%.The business’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company earned ($2.82) EPS. As a group, analysts anticipate that Neogen Corporation will post 0.22 earnings per share for the current fiscal year.

Trending Headlines about Neogen

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Neogen reported fiscal Q4 adjusted earnings of $0.09 per share, above the $0.05 analyst consensus and substantially better than the $2.82-per-share loss reported in the year-ago quarter. Revenue of $225.3 million also exceeded estimates of $212.35 million. Neogen Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Management forecast fiscal 2027 revenue of $880 million to $885 million, above the $851.1 million consensus estimate. First-quarter fiscal 2027 revenue guidance of $207 million to $209 million also topped the $204.9 million consensus. Neogen Fiscal 2027 Guidance
• Positive Sentiment: The company expects fiscal 2027 adjusted EBITDA of approximately $180 million to $182 million, signaling anticipated improvement in profitability and supporting the favorable investor reaction. Neogen Fiscal 2026 Results
• Neutral Sentiment: Despite the earnings beat, quarterly revenue was essentially flat year over year, down 0.1%, indicating that the stronger outlook depends on future growth rather than current top-line acceleration.
• Neutral Sentiment: Analysts’ average price target is approximately $10.67, below the stock’s recent trading level, suggesting valuation and expectations may limit additional upside. Analysts Set Neogen Price Target
• Negative Sentiment: Neogen plans to increase research and development spending by roughly 50% in fiscal 2027. Although intended to support longer-term growth, the investment could pressure near-term margins and earnings.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.